Drug Trial Radar · NCT07615985
Phase 1a Study Assessing Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PMG1016
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Pulmongene Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a first-in-human (FIH), randomized, double-blind, placebo-controlled study of PMG1016 in healthy adult participants. It aims to investigate the safety, tolerability, PK, and immunogenicity of PMG1016 administered via IV infusion. Cohort 1: Healthy participants receiving single doses of PMG1016 Dose 1 or placebo. Cohort 2: Healthy participants receiving single doses of PMG1016 Dose 2 or placebo. Cohort 3: Healthy participants receiving single doses of PMG1016 Dose 3 or placebo. Cohort 4: Healthy participants receiving single doses of PMG1016 Dose 4 or placebo.
Conditions
- Chronic Kidney Disease
Interventions
PMG1016 Dose 1Drug
Participants will be administered PMG1016 Dose 1 or Placebo in a 100mL IV infusion Volume
PMG1016 Dose 2Drug
Participants will be administered PMG1016 Dose 2 or Placebo in a 100mL IV infusion Volume
PMG1016 Dose 3Drug
Participants will be administered PMG1016 Dose 3 or Placebo in a 100mL IV infusion Volume
PMG1016 Dose 4Drug
Participants will be administered PMG1016 Dose 4 or Placebo in a 100mL IV infusion Volume
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs)Time frame: Day 1 to Day 57
- Serious adverse events (SAEs)Time frame: From Day 1 to Day 57
- Number of participants with abnormal pulse rateTime frame: From Day 1 to Day 57
- Number of participants with abnormal blood pressureTime frame: From Day 1 to Day 57
- Number of participants with abnormal respiratory rateTime frame: From Day 1 to Day 57
- Number of participants with abnormal tympanic temperatureTime frame: From Day 1 to Day 57
- Number of Participants with Clinically Significant Abnormal PR IntervalTime frame: From Day 1 to Day 57
- Number of Participants with Clinically Significant Abnormal QRS DurationTime frame: From Day 1 to Day 57
- Number of Participants with Clinically Significant Abnormal QT intervalTime frame: From Day 1 to Day 57
- Number of Participants with Clinically Significant Abnormal RR intervalTime frame: From Day 1 to Day 57
- Number of Participants with Clinically Significant Valvular AbnormalitiesTime frame: Day 1 to Day 29
- Number of Participants with Clinically Significant Abnormal Left Ventricular Ejection FractionTime frame: Day 1 to Day 29
- Number of Participants with Clinically Significant Abnormal Hematology ResultsTime frame: Day 1 to Day 57
- Number of Participants with Clinically Significant Abnormal Clinical Chemistry ResultsTime frame: Day 1 to Day 57
- Number of Participants with Clinically Significant Abnormal Urinalysis ResultsTime frame: Day 1 to Day 57
- Number of Participants with Clinically Significant Abnormal Physical Examination FindingsTime frame: Day 1 to Day 57
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network (Brisbane)
Brisbane, Queensland, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.